Predictors of patients’ choices for breast-conserving therapy or mastectomy: a prospective study

por Molenaar, S, Oort, F, Sprangers, M, Rutgers, E, Luiten, E, Mulder, J, de Haes, H
Publicado 2004

Immunohistochemical categorisation of ductal carcinoma in situ of the breast

por Meijnen, P, Peterse, J L, Antonini, N, Rutgers, E J Th, van de Vijver, M J
Publicado 2008

Detection of metastases in sentinel lymph nodes of breast cancer patients by multiple mRNA markers

por Weigelt, B, Verduijn, P, Bosma, A J, Rutgers, E J, Peterse, H L, van't Veer, L J
Publicado 2004

Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature

por Knauer, M, Cardoso, F, Wesseling, J, Bedard, P L, Linn, S C, Rutgers, E J T, van 't Veer, L J
Publicado 2010

The influence of tamoxifen treatment on the oestrogen receptor in metachronous contralateral breast cancer

por Kaas, R, Peterse, J L, Hart, A A M, Voogd, A C, Rutgers, E J T, van Leeuwen, F E
Publicado 2003

Effects of patient selection on the applicability of results from a randomised clinical trial (EORTC 10853) investigating breast-conserving therapy for DCIS

por Bijker, N, Peterse, J L, Fentiman, I S, Julien, J-P, Hart, A A M, Avril, A, Cataliotti, L, Rutgers, E J T
Publicado 2002

Photodynamic therapy as adjuvant therapy in surgically treated pleural malignancies.

por Baas, P., Murrer, L., Zoetmulder, F. A., Stewart, F. A., Ris, H. B., van Zandwijk, N., Peterse, J. L., Rutgers, E. J.
Publicado 1997

Efficacy of up-front 5-fluorouracil-epidoxorubicin-cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients.

por van der Wall, E., Rutgers, E. J., Holtkamp, M. J., Baars, J. W., Schornagel, J. H., Peterse, J. L., Beijnen, J. H., Rodenhuis, S.
Publicado 1996

Molecular Imaging in Breast Cancer: From Whole-Body PET/CT to Dedicated Breast PET

por Koolen, B. B., Vogel, W. V., Vrancken Peeters, M. J. T. F. D., Loo, C. E., Rutgers, E. J. Th., Valdés Olmos, R. A.
Publicado 2012

Impact of non-axillary sentinel node biopsy on staging and treatment of breast cancer patients

por Tanis, P J, Nieweg, O E, Valdés Olmos, R A, Peterse, J L, Rutgers, E J Th, Hoefnagel, C A, Kroon, B B R
Publicado 2002

Long-term impact of the 70-gene signature on breast cancer outcome

por Drukker, C. A., van Tinteren, H., Schmidt, M. K., Rutgers, E. J. Th., Bernards, R., van de Vijver, M. J., van’t Veer, L. J.
Publicado 2014

The Relevance of Breast Cancer Subtypes in the Outcome of Neoadjuvant Chemotherapy

por Straver, M. E., Rutgers, E. J. Th., Rodenhuis, S., Linn, S. C., Loo, C. E., Wesseling, J., Russell, N. S., Oldenburg, H. S. A., Antonini, N., Vrancken Peeters, M. T. F. D.
Publicado 2010

Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers

por van Sprundel, T C, Schmidt, M K, Rookus, M A, Brohet, R, van Asperen, C J, Rutgers, E J Th, van‘t Veer, L J, Tollenaar, R A E M
Publicado 2005

Mammographic screening detects low-risk tumor biology breast cancers

por Drukker, C. A., Schmidt, M. K., Rutgers, E. J. T., Cardoso, F., Kerlikowske, K., Esserman, L. J., van Leeuwen, F. E., Pijnappel, R. M., Slaets, L., Bogaerts, J., van’t Veer, L. J.
Publicado 2014

High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approach.

por van der Wall, E., Nooijen, W. J., Baars, J. W., Holtkamp, M. J., Schorangel, J. H., Richel, D. J., Rutgers, E. J., Slaper-Cortenbach, I. C., van der Schoot, C. E., Rodenhuis, S.
Publicado 1995

Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy

por van Roozendaal, L. M., Goorts, B., Klinkert, M., Keymeulen, K. B. M. I., De Vries, B., Strobbe, L. J. A., Wauters, C. A. P., van Riet, Y. E., Degreef, E., Rutgers, E. J. T., Wesseling, J., Smidt, M. L.
Publicado 2016

Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms

por Drukker, C. A., Nijenhuis, M. V., Bueno-de-Mesquita, J. M., Retèl, V. P., van Harten, W. H., van Tinteren, H., Wesseling, J., Schmidt, M. K., van’t Veer, L. J., Sonke, G. S., Rutgers, E. J. T., van de Vijver, M. J., Linn, S. C.
Publicado 2014

Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON study

por Wevers, M. R., Schmidt, M. K., Engelhardt, E. G., Verhoef, S., Hooning, M. J., Kriege, M., Seynaeve, C., Collée, M., van Asperen, C. J., Tollenaar, R. A. E. M., Koppert, L. B., Witkamp, A. J., Rutgers, E. J. T., Aaronson, N. K., Rookus, M. A., Ausems, M. G. E. M.
Publicado 2015

Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2

por Ligtenberg, M J L, Hogervorst, F B L, Willems, H W, Arts, P J W, Brink, G, Hageman, S, Bosgoed, E A J, Looij, E Van der, Rookus, M A, Devilee, P, Vos, E M A W, Wigbout, G, Struycken, P M, Menko, F H, Rutgers, E J Th, Hoefsloot, E H, Mariman, E C M, Brunner, H G, Veer, L J Van't
Publicado 1999

Impact of rapid genetic counselling and testing on the decision to undergo immediate or delayed prophylactic mastectomy in newly diagnosed breast cancer patients: findings from a r...

por Wevers, M R, Aaronson, N K, Verhoef, S, Bleiker, E M A, Hahn, D E E, Kuenen, M A, van der Sanden-Melis, J, Brouwer, T, Hogervorst, F B L, van der Luijt, R B, Valdimarsdottir, H B, van Dalen, T, Theunissen, E B M, van Ooijen, B, de Roos, M A, Borgstein, P J, Vrouenraets, B C, Vriens, E, Bouma, W H, Rijna, H, Vente, J P, Witkamp, A J, Rutgers, E J T, Ausems, M G E M
Publicado 2014